Compare Alphabet Inc Class A (GOOGL) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Organon & Co. Common Stock — how do they compare? Alphabet Inc Class A trades at $342.49 (market cap $4.30T), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Alphabet Inc Class A is far larger — about 1187.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Organon & Co. Common Stock for 0 Days on average.
| GOOGL | OGN | |
|---|---|---|
Market Cap | $4.30T | $3.62B |
Volume | 22,270,289 | 2,892,999 |
Sector | Media | Health |
52-Week High | $402.62 | $13.81 |
52-Week Low | $250.46 | $5.70 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.19T | $11.04B |
Dividend Yield | 0.25% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $347.64, down 1.44% today, but maintains strong technical support near $344-$350. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 54.77% net margin. Recent earnings beats and strong analyst consensus support the bullish outlook, with 87% of analysts rating it a Buy. Technical indicators show bullish moving averages but overbought RSI conditions.
Alphabet presents a compelling investment case with strong AI-driven growth, consistent earnings outperformance, and dominant market positioning. Key risks include regulatory scrutiny, competitive pressures in AI, and market volatility. With a consensus price target of $430.96 representing 24% upside potential, the stock offers attractive long-term value despite short-term technical overbought conditions.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
